echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Lancet Haemat: Long-term prognosis of Bentuximab combined with chemotherapy in the treatment of stage III/IV classic Hodgkin’s lymphoma

    Lancet Haemat: Long-term prognosis of Bentuximab combined with chemotherapy in the treatment of stage III/IV classic Hodgkin’s lymphoma

    • Last Update: 2021-09-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Although with the introduction of PET adaptation programs, the treatment of Hodgkin's lymphoma has made considerable progress, but the problems faced in practical applications hinder the wider application of these methods
    .


    The ECHELON-1 study evaluated the first-line A+AVD (bentuximab+doxorubicin+vinblastine+dacarbazine) versus ABVD (doxorubicin+bleomycin+vinblastine+dacarbazine) regimen For the efficacy and safety of stage III or IV classic Hodgkin's lymphoma


    Lymphoma

    This article reports the latest analysis results of the ECHELON-1 study after 5 years of follow-up
    .

    This article reports the latest analysis results of the ECHELON-1 study after 5 years of follow-up
    .


    The ECHELON-1 study is an international, open-label, randomized phase 3 trial carried out in 218 clinical centers in 21 countries, recruiting untreated patients with stage III or IV classic Hodgkin’s lymphoma who are over 18 years of age.
    1:1 randomized to receive A+AVD or ABVD treatment for 6 courses
    .


    The primary endpoint is adjusted progression-free survival


    From November 19, 2012 to January 13, 2016, a total of 1334 patients received A+AVD (n=664) or ABVD (n=670) at random
    .


    After a median follow-up of 60.


    The 5-year progression-free survival rates of the A+AVD group and the ABVD group were 82.


    5-year progression-free survival rate of patients in the A+AVD group and ABVD group

    5-year progression-free survival rate of patients in the A+AVD group and ABVD group

    Among patients with negative PET2, the 5-year progression-free survival rates of the A+AVD group and the ABVD group were 84.
    9% (95% CI 81.
    7–87.
    6) and 78.
    9% (75.
    2–82.
    1; HR 0.
    66 [95% CI 0.
    50–0 ·88]; p=0.
    0035)
    .


    The 5-year progression-free survival rates of PET2-positive patients in the A+AVD group and ABVD group were 60.


    In PET2-negative patients, the 5-year progression-free survival rates of the A+AVD group and ABVD group were 84.


    In summary, after 5 years of follow-up, regardless of the status of PET-2, compared with the ABVD regimen, the A+AVD regimen showed a strong and lasting improvement in the progression-free survival rate of stage III or IV classic Hodgkin’s lymphoma.
    , And the security is consistent
    .


    Based on these findings, the A+AVD regimen should be preferred for patients with stage III or IV classic Hodgkin’s lymphoma who have not been treated before


    Compared with the ABVD regimen, the A+AVD regimen has shown a strong and lasting improvement in the progression-free survival rate of stage III or IV classic Hodgkin’s lymphoma.


    Original source:

    David J Straus, et al.


    Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.